

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5281542

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROCHE GLYCART AG	06/08/2017
RECEIVING PARTY DATA	
Name:	F. HOFFMANN-LA ROCHE AG
Street Address:	124 GRENZACHERSTRASSE
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	CH-4070
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15944394
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-225-2497
Email:	nikkin@gene.com
Correspondent Name:	NIKKI NOMURA
Address Line 1:	1 DNA WAY, MS-49
Address Line 2:	C/O GENENTECH, INC.
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P34215-US
NAME OF SUBMITTER:	NIKKI NOMURA
SIGNATURE:	/Nikki NOMURA/
DATE SIGNED:	12/13/2018
Total Attachments: 2	
source=P34215-US - Assignment 4 (Roche_Glycart_to_FHLR)#page1.tif	
source=P34215-US - Assignment 4 (Roche_Glycart_to_FHLR)#page2.tif	

ASSIGNMENT AGREEMENT

Roche Glycart AG ("ASSIGNOR") a corporation duly organized under the laws of Switzerland and having its principal place of business at Wagistrasse 18, CH-8952 Schlieren, Switzerland

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.	Country	Filing Date	Serial No.
P34215	Europe	5 April 2017	17165125.0

entitled

BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.





This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR**Roche Glycart AG**

Basel, Switzerland, June 8, 2017

Place, Date



Antonio Natoli



Susanne Amann

both duly authorized signatories

ASSIGNEE**F. Hoffmann-La Roche AG**

Basel, Switzerland, June 8, 2017

Place, Date

Thomas Winkler
Holder of procurationIna Gengelbach
Mandatory**Legalization**

The undersigned Notary Public of the Canton of Basel-Stadt (Switzerland), Dr. Christoph Nertz, herewith legalizes the foregoing signature of

Roche Glycart AG, a stock company with legal domicile in Schlieren (Switzerland), rendered by

Mister Antonio Natoli, citizen of and residing in Basel (Switzerland), and

Miss Susanne Amann, German citizen, residing in Heitersheim (Germany),

both duly entitled to sign documents wherein property of the company is alienated.

He also legalizes the overleaf signature of

F. Hoffmann-La Roche AG, a stock company with legal domicile in Basel (Switzerland), rendered by

Mister Dr. Thomas Winkler, German citizen, residing in Riehen (Switzerland), and

Miss Ina Gengelbach, German citizen, residing in Grenzach-Wyhlen (Germany),

both duly entitled to sign documents wherein property of the company is alienated.

All signers and signatures personally known to the Notary.

B a s e l (Switzerland), this 13th (thirteenth) day of June 2017 (two thousand and seventeen).

